Inhibition of VEGFR3 preferentially affects CD133+ OCSCs, leading to the downregulation of BRCA1 and BRCA2, and thereby restoring chemosensitivity in previously resistant ovarian cancer cell lines [236]. Here, PROM1 is linked to ovarian carcinoma.